Chief executive, Regenxbio
Appears in 1 story
Leading FDA submission for RGX-202
For three years, Sarepta Therapeutics has been the only company in the world selling a gene therapy for Duchenne muscular dystrophy. Regenxbio's trial result on May 14, 2026, sets up a second contender for U.S. Food and Drug Administration (FDA) approval.
Updated May 14
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
